Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1981 Nov-Dec;65(11-12):1021-6.

Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study

C B Pratt, A Hayes, A A Green, W E Evans, N Senzer, C B Howarth, J L Ransom, W Crom
  • PMID: 7197583
Clinical Trial

Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study

C B Pratt et al. Cancer Treat Rep. 1981 Nov-Dec.

Abstract

In a phase II trial, cisplatin was given by two randomly assigned dose schedules to 53 children with malignant solid tumors. Both schedules, 30 mg/m2/week and 90 mg/m2 every 3 weeks, were associated with drug-related toxic effects involving the renal, hematopoietic, and neuromuscular systems. Pharmacokinetic studies indicated that the initial serum half-life of total platinum was 27.6 minutes, with a terminal half-life of 44.4 hours. Significant antitumor effect was noted in patients with neuroblastoma and malignant germ cell tumors. Use of cisplatin in combination therapy for patients with these diseases is indicated.

PubMed Disclaimer

Publication types

MeSH terms